Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.
|Videos|April 26, 2018
Small-Molecule TKIs: Potential Benefit in Multiple Malignancies
Author(s)Brian Schwartz, MD
In this video, Dr. Brian Schwartz highlights several small-molecule TKIs in development with the potential to help patients with several malignancies.
Advertisement
In this video, Dr. Brian Schwartz highlights several small-molecule TKIs in development with the potential to help patients with several malignancies.
Advertisement
Related to this article
“No one should be excluded from any clinical trial,” said Paul G. Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies.
Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.
“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.
Jan Kitajewski, PhD, discussed how pooled expertise, pilot funding, and investigator support help move bench discoveries toward multicenter trials.
Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.
Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with HIV-associated lymphoma.
Nitin Ohri, MD, MS, discusses how his team manages toxicity and treatment tolerance as combination regimens grow more complex.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
3
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
4
Considering Talquetamab and Emerging Bispecifics in R/R Multiple Myeloma
5